Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
- Latest News
- Most Popular
- Correction or Summer Range Trade?
- Hitting Home Runs & Grand Slams, Not Loud Outs
- Machinery Industry Stock Outlook - May 2013
- Determining Correct Position Size with Options
- This Week's Growth & Income Stocks
- RTI: Do Stocks Tank When QE Ends?
- 3 Top-Ranked Consumer ETFs to Buy Now
- Who Wants to Keep "Too Big to Fail" Alive?
- Debt-Ceiling Alarm Bell Tolls
- Avoid These 3 Eurozone ETFs This Summer
- AWS 5/23: Is the Market Over-Reacting?
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/23/2013
| Company Name | Symbol | %Change |
|---|---|---|
| WESTELL TECH | WSTL | 6.67% |
| STEIN MART I | SMRT | 5.38% |
| ALLIANCE FIB | AFOP | 5.21% |
| DAWSON GEOPH | DWSN | 4.33% |
| MARRIOTT VAC | VAC | 3.27% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Isis Pharmaceuticals Inc. ( ISIS - Analyst Report ) and AstraZeneca ( AZN - Analyst Report ) recently announced that they have entered into an agreement to discover and develop five new generation antisense oncology drugs, including ISIS-STAT3Rx.
ISIS-STAT3Rx is being developed for advanced lymphomas patients. In October 2012, Isis Pharma had reported preliminary results from a dose escalation phase I study of ISIS-STAT3Rx. The candidate demonstrated encouraging efficacy in treatment-refractory advanced cancer patient and a promising safety profile. Currently, a phase II trial is ongoing in patients with advanced lymphomas.
As per the terms of the agreement, Isis Pharma will receive upfront and near-term payments of $31 million ($25 million on the signing of the agreement and $6 million in the second quarter of 2013) from AstraZeneca. AstraZeneca will also undertake all the development and commercialization responsibilities of ISIS-STAT3Rx (apart from the ongoing trial) and has an option to license other products.
AstraZeneca is also obligated to pay Isis Pharma milestone payments and royalties on the sale of commercialized products.
Our Take
We are positive on this agreement which provides Isis Pharma with funds in the form of upfront, milestone and other payments. We believe that antisense technology (the main area of focus at Isis Pharma) represents an exciting and potentially revolutionary platform for developing therapeutic candidates to treat a wide margin of diseases.
The company has partnership agreements with leading pharmaceuticals companies like Biogen ( BIIB - Analyst Report ) , Sanofi ( SNY - Analyst Report ) , Eli Lilly ( LLY - Analyst Report ) and GlaxoSmithKline ( GSK - Analyst Report ) among others. We note that Sanofi currently holds a Zacks #2 Rank (Buy) in the short run.
Isis Pharma has a major regulatory event coming up next month when the Food and Drug Administration’s (FDA) is expected to respond on the company’s marketing application for lead pipeline candidate, Kynamro (mipomersen). We expect investor focus to remain on the FDA’s decision.
Read the full Analyst Report on AZN
Read the full Analyst Report on ISIS
Read the full Analyst Report on SNY
Read the full Analyst Report on LLY
Read the full Analyst Report on GSK
Read the full Analyst Report on BIIB